2020
DOI: 10.1017/s1092852920001285
|View full text |Cite
|
Sign up to set email alerts
|

Valproate for schizophrenia: ambrosia?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
2
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 13 publications
0
2
0
Order By: Relevance
“…Valproate confers neuroprotection as a bonanza. 5 It has been shown in COVID delirium-catatonia composite presentation is at times difficult to brush out, and given the differential response to antipsychotics-benzodiazepines, some authors have suggested deploying amantadine. Amantadine has dopaminomimetic, weak anticholinergic and antiglutamate actions that can be helpful in these complex clinical scenarios.…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Valproate confers neuroprotection as a bonanza. 5 It has been shown in COVID delirium-catatonia composite presentation is at times difficult to brush out, and given the differential response to antipsychotics-benzodiazepines, some authors have suggested deploying amantadine. Amantadine has dopaminomimetic, weak anticholinergic and antiglutamate actions that can be helpful in these complex clinical scenarios.…”
mentioning
confidence: 99%
“…Since multifocal myoclonus and seizures are fairly commonplace in COVID deliria, use of broad-spectrum antiepileptic drugs like valproate can be justified to target agitation as well. Valproate confers neuroprotection as a bonanza 5 …”
mentioning
confidence: 99%